Rinvecalinase Alfa Preeclampsia Therapeutics Market

Rinvecalinase alfa therapy accounts for 33.0% of the rinvecalinase alfa preeclampsia therapeutics market by treatment type. Early-onset preeclampsia leads the indication category with 30.3%, while intravenous administration holds 42.3% of the route-of-administration segment.